Verve Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021
Market Capitalization	483	889	1,192	1,776
Market Cap Growth	-	-25.45%	-32.88%	-
Enterprise Value	-81	325	702	1,410
PE Ratio	-4.44	-4.44	-7.57	-14.76
PS Ratio	41.08	75.58	614.13	-
PB Ratio	0.81	1.48	2.16	4.97
P/FCF Ratio	-5.60	-5.60	-8.79	-21.60
P/OCF Ratio	-5.94	-5.94	-9.74	-22.81
EV/Sales Ratio	27.62	27.62	361.88	-
EV/EBITDA Ratio	-1.73	-1.73	-4.66	-12.06
EV/EBIT Ratio	-1.63	-1.63	-4.46	-11.72
EV/FCF Ratio	-2.04	-2.04	-5.18	-17.15
Debt / Equity Ratio	0.11	0.11	0.13	-
Debt / EBITDA Ratio	-0.35	-0.35	-0.46	-
Debt / FCF Ratio	-0.41	-0.41	-0.52	-
Quick Ratio	17.15	17.15	15.98	16.60
Current Ratio	17.24	17.24	16.05	16.67
Asset Turnover	0.02	0.02	0.00	0
Return on Equity (ROE)	-39.30%	-39.30%	-36.50%	-44.90%
Return on Assets (ROA)	-30.90%	-30.90%	-31.10%	-34.90%
Return on Capital (ROIC)	-33.59%	-33.59%	-26.68%	-24.36%
Earnings Yield	-41.42%	-22.51%	-13.20%	-6.77%
FCF Yield	-32.88%	-17.87%	-11.37%	-4.63%
Buyback Yield / Dilution	-18.79%	-18.79%	-101.04%	-1094.26%
Total Shareholder Return	-18.79%	-18.79%	-101.04%	-1094.26%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).